thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-02. Numbers and descriptions here follow the published literature rather than marketing material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
A 2017 report conducted by Beijing LGBT Center and Peking University showed that out of 1279 of its respondents who wanted to receive hormone treatment, 71% of them felt that it was "difficult", "very difficult", or "virtually impossible" to acquire safe and reliable information about gender affirming medications and receive hormonal replacement therapy with the guidance of a doctor. As a result, 66% of the respondents chose "online" and 51% chose "friends" as one of their sources for hormone replacement therapy medications. Gender reassignment surgeries were reported to be similarly inaccessible, with 89.1% of the respondents who have the needs for such surgeries unable to pursue them. On December 1, 2022, the Chinese National Medical Products Administration banned online sales of cyproterone acetate, estradiol, and testosterone, which are the most common hormones and antiandrogens used in transgender hormone replacement therapy.
== Staff == The Teaching and Research Staff (TRS) of the department consists of about 150 people (Professors, Associate Professors, Assistant Professors, Lecturers). Members EIB / ACC, administrative staff is 36 people.
=== N05CM Other hypnotics and sedatives === N05CM01 Methaqualone N05CM02 Clomethiazole N05CM03 Bromisoval N05CM04 Carbromal N05CM05 Scopolamine N05CM06 Propiomazine N05CM07 Triclofos N05CM08 Ethchlorvynol N05CM10 Hexapropymate N05CM11 Bromides N05CM12 Apronal N05CM13 Valnoctamide N05CM15 Methylpentynol N05CM16 Niaprazine N05CM18 Dexmedetomidine N05CM20 Diphenhydramine N05CM22 Promethazine N05CM25 Magnesium aspartate hydrobromide N05CM26 Magnesium glutamate hydrobromide N05CM27 Doxylamine
== History == SDA was first mentioned in the scientific literature by 2013, but was only conceptually described at this time. Subsequently, its synthesis and preclinical pharmacology were described by Nina Kastner and colleagues including Matthias Grill at MiHKAL in 2025. Prodrugs of SDA and/or related compounds have also been described.
Sources: en.wikipedia.org
===== Nanocubes ===== Silver nanocubes can be synthesized using ethylene glycol as a reducing agent and PVP as a capping agent, in a polyol synthesis reaction (vide supra). A typical synthesis using these reagents involves adding fresh silver nitrate and PVP to a solution of ethylene glycol heated at 140 °C. This procedure can actually be modified to produce another anisotropic silver nanostructure, nanowires, by just allowing the silver nitrate solution to age before using it in the synthesis. By allowing the silver nitrate solution to age, the initial nanostructure formed during the synthesis is slightly different than that obtained with fresh silver nitrate, which influences the growth process, and therefore, the morphology of the final product. Nanorods, Nanobars, and Nanowires Silver nanorods (also categorized as nanobars or nanowires depending on their aspect ratio), are a class of anisotropic nanoparticles extensively studied for their tunable electrical and optical properties. Their morphology is typically controlled by selective capping agents during the synthesis. For instance, polyvinylpyrrodine (PVP) can strongly bind to the {100} facets of silver seeds while interacting more weakly with the {111} facets. This preferential adsorption restricts growth on the {100} surfaces and promotes elongation at the <110> direction, ultimately resulting in the formation of rod-like structures.
The Space Race (Russian: космическая гонка, romanized: kosmicheskaya gonka, IPA: [kɐsˈmʲitɕɪskəjə ˈɡonkə]) was a 20th-century competition between the Cold War rivals, the United States and the Soviet Union, to achieve superior spaceflight capability. It had its origins in the ballistic missile-based nuclear arms race between the two nations that followed World War II and the onset of the Cold War. The technological advantage demonstrated by spaceflight achievement was seen as necessary for national security, particularly in regard to intercontinental ballistic missile and satellite reconnaissance capability, but also became part of the cultural symbolism and ideology of the time. The Space Race brought pioneering launches of artificial satellites, robotic landers to the Moon, Venus, and Mars, and human spaceflight in low Earth orbit and ultimately to the Moon. Public interest in space travel originated in the 1951 publication of a Soviet youth magazine and was promptly picked up by US magazines. The competition began on July 29, 1955, when the United States announced its intent to launch artificial satellites for the International Geophysical Year. Five days later, the Soviet Union responded by declaring they would also launch a satellite "in the near future". The launching of satellites was enabled by developments in ballistic missile capabilities since the end of World War II. The competition gained Western public attention with the "Sputnik crisis", when the USSR achieved the first successful satellite launch, Sputnik 1, on October 4, 1957.
Lung fibrosis is a recognized complication of rheumatoid arthritis. It is also a rare but well-recognized consequence of medications used to treat RA such as methotrexate and leflunomide). Caplan's syndrome describes lung nodules in individuals with RA and additional exposure to coal dust. Exudative pleural effusions are also associated with RA.
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.